Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients
Joint Authors
Bashir, Salah O.
Umar, Haydar A.
Aamir, Mahmud A.
Sumali, Rashid
Mursi, Muhammad D.
Source
Saudi Journal of Kidney Diseases and Transplantation
Issue
Vol. 26, Issue 6 (31 Dec. 2015), pp.1135-1141, 7 p.
Publisher
Saudi Center for Organ Transplantation
Publication Date
2015-12-31
Country of Publication
Saudi Arabia
No. of Pages
7
Main Subjects
Topics
Abstract EN
Secondary hyperparathyroidism is almost a constant feature in chronic kidney disease (CKD) patients maintained on hemodialysis (HD).
Calcimimetic agents appear to offer an alternative to surgery in controlling secondary hyperparathyroidism in these patients.
Recent studies provide conflicting data on the benefits, efficacy and tolerance of cinacalcet as first-line therapy for the treatment of secondary hyperparathyroidism in CKD.
This study was designed to investigate the efficacy and tolerance of a low dose of the calcimimetic agent cinacalcet in patients on long-term HD having moderate to severe secondary hyperparathyroidism.
Twentyfive adult male patients on HD for more than three years were included in the study.
All had moderate to severe secondary hyperparathyroidism with serum intact parathyroid hormone (iPTH) >50 pmol/L, resistant to conventional treatment.
We used the targets of Chronic Kidney Disease: Outcomes Quality Initiative (K/DOQI) clinical guidelines as optimal target of serum iPTH, calcium and phosphate.
Patients were administered cinacalcet as a single oral daily dose of 30 mg and were followed-up for six months.
Cinacalcet treatment for six months resulted in a significant reduction in the serum phosphate and iPTH levels while the serum calcium levels remained unchanged.
Thirty-six percent of the patients attained the recommended serum iPTH levels, 40% achieved significant reduction of the serum iPTH levels and 24% showed no favorable response.
Only one patient dropped out because of severe gastrointestinal symptoms.
Our results suggest that treatment of CKD patients, having moderate to severe secondary hyperparathyroidism, with low-dose cinacalcet is effective and well tolerated.
American Psychological Association (APA)
Bashir, Salah O.& Umar, Haydar A.& Aamir, Mahmud A.& Sumali, Rashid& Mursi, Muhammad D.. 2015. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation،Vol. 26, no. 6, pp.1135-1141.
https://search.emarefa.net/detail/BIM-629570
Modern Language Association (MLA)
Bashir, Salah O.…[et al.]. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation Vol. 26, no. 6 (Nov. / Dec. 2015), pp.1135-1141.
https://search.emarefa.net/detail/BIM-629570
American Medical Association (AMA)
Bashir, Salah O.& Umar, Haydar A.& Aamir, Mahmud A.& Sumali, Rashid& Mursi, Muhammad D.. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients. Saudi Journal of Kidney Diseases and Transplantation. 2015. Vol. 26, no. 6, pp.1135-1141.
https://search.emarefa.net/detail/BIM-629570
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 1140-1141
Record ID
BIM-629570